Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer
Authors:
- Zhenghong YuZYZhenghong Yu
- Tingting WangTWTingting Wang
- Junwen ZhangJZJunwen Zhang
- Lingzhi HongLHLingzhi Hong
- Longbang ChenLCLongbang Chen
- 1 May 2007
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 56 (2) , 289-294
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Methylation of RAS association domain family protein 1A as a biomarker of lung cancerCancer, 2006
- Frequent inactivation of RASSF1A, BLU, and SEMA3B on 3p21.3 by promoter hypermethylation and allele loss in non-small cell lung cancerCancer Letters, 2005
- Clinicopathological significance of aberrant methylation of RARβ2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients with non-small cell lung cancerLung Cancer, 2004
- RASSF1A gene inactivation in non‐small cell lung cancer and its clinical implicationInternational Journal of Cancer, 2003
- Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patientsCancer Letters, 2003
- Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patientsOncogene, 2003
- Role of biomarkers for early detection of lung cancer and chemopreventionEuropean Respiratory Journal, 2002
- Estimating the world cancer burden: Globocan 2000International Journal of Cancer, 2001
- Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.Proceedings of the National Academy of Sciences of the United States of America, 1996
- Neoplastic Characteristics of the DNA Found in the Plasma of Cancer PatientsOncology, 1989